MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

KalVista Pharmaceuticals Inc

Suletud

SektorTervishoid

11.11 -3.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

10.99

Max

11.76

Põhinäitajad

By Trading Economics

Sissetulek

-6.2M

-49M

Aktsiakasum

-0.92

Kasumimarginaal

-3,702.322

Töötajad

150

EBITDA

4.4M

-41M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+128.16% upside

Turustatistika

By TradingEconomics

Turukapital

586K

593M

Eelmine avamishind

14.75

Eelmine sulgemishind

11.11

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

KalVista Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. nov 2024, 21:11 UTC

Suurimad hinnamuutused turgudel

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Võrdlus sarnastega

Hinnamuutus

KalVista Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

128.16% tõus

12 kuu keskmine prognoos

Keskmine 26.33 USD  128.16%

Kõrge 39 USD

Madal 18 USD

Põhineb 10 Wall Streeti analüütiku instrumendi KalVista Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 12.5Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.